Congenital Myasthenia SyndromePhase 1NCT07830563
Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome
A Phase 1 study testing AMP-101 in people with Congenital Myasthenia Syndrome, run by Amplo Biotechnology.
Trial summary
This study is evaluating the safety and potential effects of AMP-101 in people with DOK7 Congenital Myasthenia Syndrome (CMS). Participants will receive a single dose of the study treatment and will be monitored to assess their health and response to treatment. Read more about this study
- Who is it for?
- Ages 7 years and older
- Conditions the study is for
- Congenital Myasthenia Syndrome
- What is being tested?
- AMP-101
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Oct 2031
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- A diagnosis of moderate to severe DOK7 CMS as defined by:
- genetic mutation analysis,
- demonstrated clinical findings such as limb girdle muscle weakness,
- exercise intolerance.
- Is willing to discontinue drugs known to worsen symptoms in DOK7 CMS patients such as 3,4-diaminopyridine (3,4-DAP) and pyridostigmine at least 1 month prior to Day 1.
- If being treated with oral salbutamol, is clinically stable, and plans to remain on the same dose for the duration of the study through to EoS (approximately 6 months) - unless a change in dose is medically indicated at the discretion of the PI or designee.
- If discontinuing oral salbutamol, is clinically stable, and has been off the medication for at least 1 month prior to Day 1 - unless a change in dose is clinically indicated at the discretion of the PI or designee.
- Not pregnant or breastfeeding, or willing to cease breastfeeding.
Who cannot join
- Active infections including Epstein-Barr virus (EBV), cytomegalovirus (CMV), positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), human immunodeficiency virus (HIV) antibody.
- Have required oral or systemic corticosteroids within the last 14 days prior to Screening.
- Rh74 AAV capsid binding antibody titers > 1:100 as determined by ELISA immunoassay.
- Platelet count below the lower limit of normal (LLN) at Screening.
- Have received other gene transfer/gene therapy agents.
- Clinically significant liver dysfunction, including significant hepatic fibrosis, liver cirrhosis of any etiology identified by liver ultrasound or other imaging modalities, portal hypertension, or a history of hepatic malignancy.
- Current or history of clinically significant respiratory failure, including the requirement for long-term supplemental oxygen therapy, non-invasive ventilation, mechanical ventilation, or other evidence of severe respiratory impairment, as determined by medical history, physical examination, or pulmonary function assessment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A First-In-Human, Phase 1, Open-Label, Non-Randomized, Single Dose Study to Assess the Safety, Tolerability and Preliminary Efficacy of AMP-101 in Participants Diagnosed With DOK7 Congenital Myasthenic Syndrome
This study is evaluating the safety and potential effects of AMP-101 in people with DOK7 Congenital Myasthenia Syndrome (CMS). Participants will receive a single dose of the study treatment and will be monitored to assess their health and response to treatment. Approximately 4 participants are expected to take part in the study.
- Conditions
- Congenital Myasthenia Syndrome
- Being tested
- AMP-101
- Medical subject headings
- Myasthenic Syndromes, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AMP-101Drug
Route of Administration: intravenous infusion Unit Dose Strength: 5.02 x10^13 Vg/ml in a volume of 1 mL/vial
| Study group | Role | What they receive |
|---|---|---|
| AMP-101 | Experimental | Not described Receives: Drug: AMP-101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of TEAEs.
Measured: From Screening to Day 180 (EOT visit)
Incidence of AESIs (Adverse events of special interest)
Measured: From Screening to Day 180 (EOT visit)
Incidence of SAEs.
Measured: From Screening to Day 180 (EOT visit)
Number of participants with abnormal vital signs
Measured: From Screening to Day 180 (EOT visit)
Number of participants with abnormal ECG readings
Measured: From Screening to Day 180 (EOT visit)
Number of participants with abnormal Laboratory findings
Measured: From Screening to Day 180 (EOT visit)
Incidence of anti-AAV antibodies.
Measured: Day 28, Day 63, Day 90 and Day 180 (EOT visit)
Secondary outcomes (2)
Changes in Modified QMGS (Quantitative Myasthenia Gravis Score) from baseline
This will be assessed by a Test comprising 13 physician-evaluate items endorsed by Myasthenia Gravis Foundation of America (MGFA).
Measured: Days 1, 28, 56,90 and Day 180 (EOT visit)
Changes in MG-ADL (Myasthenia Gravis Activities of Daily Living Scale) score from baseline
This will be assessed by an 8-item patient-reported scale containing 2 items of daily life activities, and 6 items reflecting MG symptoms. The tests assess functional impact of MG using 0-3 scaling system, with scoring range from 0 to 24
Measured: Days 1, 28, 56,90 and Day 180 (EOT visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2028 (estimated)
- Study completion1 Oct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Congenital Myasthenia SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 4 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amplo Biotechnology
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07830563
- Sponsor's protocol ID
- AMP-101-001
- Status last verified
- Sep 2026
- First submitted
- 15 Sep 2026
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A First-In-Human, Phase 1, Open-Label, Non-Randomized, Single Dose Study to Assess the Safety, Tolerability and Preliminary Efficacy of AMP-101 in Participants Diagnosed With DOK7 Congenital Myasthenic Syndrome
- ClinicalTrials.gov ID
- NCT07830563
- Acronym / sponsor ID
- AMP-101-001
- Conditions
- Congenital Myasthenia Syndrome
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 4 participants (estimated)
- Lead sponsor
- Amplo BiotechnologyIndustry (pharma, biotech, devices)
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Oct 2028 (estimated)
- Study completion
- 1 Oct 2031 (estimated)
- First posted
- 21 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is evaluating the safety and potential effects of AMP-101 in people with DOK7 Congenital Myasthenia Syndrome (CMS). Participants will receive a single dose of the study treatment and will be monitored to assess their health and response to treatment. Approximately 4 participants are expected to take part in the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AMP-101 | Experimental | Drug: AMP-101 |
Who may qualify
- Ages
- 7 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- A diagnosis of moderate to severe DOK7 CMS as defined by:
- Is willing to discontinue drugs known to worsen symptoms in DOK7 CMS patients such as 3,4-diaminopyridine (3,4-DAP) and pyridostigmine at least 1 month prior to Day 1.
- If being treated with oral salbutamol, is clinically stable, and plans to remain on the same dose for the duration of the study through to EoS (approximately 6 months) - unless a change in dose is medically indicated at the discretion of the PI or designee.
- If discontinuing oral salbutamol, is clinically stable, and has been off the medication for at least 1 month prior to Day 1 - unless a change in dose is clinically indicated at the discretion of the PI or designee.
- Not pregnant or breastfeeding, or willing to cease breastfeeding.
Key exclusion criteria (7 listed)
- Active infections including Epstein-Barr virus (EBV), cytomegalovirus (CMV), positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), human immunodeficiency virus (HIV) antibody.
- Have required oral or systemic corticosteroids within the last 14 days prior to Screening.
- Rh74 AAV capsid binding antibody titers > 1:100 as determined by ELISA immunoassay.
- Platelet count below the lower limit of normal (LLN) at Screening.
- Have received other gene transfer/gene therapy agents.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AMP-101Route of Administration: intravenous infusion Unit Dose Strength: 5.02 x10^13 Vg/ml in a volume of 1 mL/vial | Drug | AMP-101 |
Primary outcome
Incidence of TEAEs.
Time frame: From Screening to Day 180 (EOT visit)
Incidence of AESIs (Adverse events of special interest)
Time frame: From Screening to Day 180 (EOT visit)
Incidence of SAEs.
Time frame: From Screening to Day 180 (EOT visit)
Number of participants with abnormal vital signs
Time frame: From Screening to Day 180 (EOT visit)
Number of participants with abnormal ECG readings
Time frame: From Screening to Day 180 (EOT visit)
Number of participants with abnormal Laboratory findings
Time frame: From Screening to Day 180 (EOT visit)
Incidence of anti-AAV antibodies.
Time frame: Day 28, Day 63, Day 90 and Day 180 (EOT visit)
2 secondary outcomes
Changes in Modified QMGS (Quantitative Myasthenia Gravis Score) from baseline
Time frame: Days 1, 28, 56,90 and Day 180 (EOT visit)
Changes in MG-ADL (Myasthenia Gravis Activities of Daily Living Scale) score from baseline
Time frame: Days 1, 28, 56,90 and Day 180 (EOT visit)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
Related trials for Congenital Myasthenia Syndrome
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Active, not recruitingObservational study
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
Congenital Myasthenic Syndrome
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingPhase 3
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
Congenital Myasthenic Syndrome, CMS
RecruitingPhase 1
Patients With Congenital Myasthenic Syndrome Will be Treated With Umbilical or Placental Derived Mesenchymal Stem Cell Exosome Solution
Congenital Myasthenic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AMP-101 in people with Congenital Myasthenia Syndrome, run by Amplo Biotechnology.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patricio Sepulveda (858-241-6835, commdev@amplobiotechnology.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of TEAEs. (time frame: From Screening to Day 180 (EOT visit)). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.